Valentina Sterlin
Family · Brooklyn, NYNPI 1932561008
Payments from drug & device makers
Across 275 payments — averaging $64.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stemline Therapeutics Inc.$4K
- AstraZeneca$3K
- Novartis$3K
- E.r. Squibb & Sons, L.L.C.$1K
- Johnson & Johnson$1K
- BD$633
- plus $5K from 34 others
What the payments were for
- Consulting fees$4,81527%
- Speaking & faculty fees$2,30513%
- Travel & lodging$1,88311%
- Food & beverage$6,03634%
- Education$6224%
- Other$2,04612%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stemline Therapeutics Inc. | 8 | $4,232 |
| AstraZeneca | 11 | $3,141 |
| Novartis | 55 | $2,639 |
| E.r. Squibb & Sons, L.L.C. | 42 | $1,178 |
| Johnson & Johnson | 25 | $1,044 |
| BD | 4 | $633 |
| Astrazeneca UK Limited | 1 | $600 |
| Daiichi Sankyo Inc. | 12 | $430 |
| Amgen | 5 | $370 |
| Ipsen Biopharmaceuticals, Inc | 6 | $296 |
| GSK | 4 | $280 |
| Gilead | 7 | $245 |
| Seagen Inc. | 6 | $223 |
| Bristol Myers Squibb | 11 | $222 |
| Sobi, Inc | 8 | $212 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $174 |
| Tersera Therapeutics LLC | 1 | $158 |
| Sanofi | 6 | $145 |
| EMD Serono, Inc. | 2 | $139 |
| Incyte Corporation | 2 | $134 |
| Pharmaessentia USA Corporation | 6 | $124 |
| Merck | 5 | $111 |
| Astellas Pharma US Inc | 5 | $107 |
| Beone Medicines USA, Inc. | 4 | $103 |
| Pfizer | 3 | $82 |
| Shield Therapeutics Inc | 4 | $76 |
| Genentech USA, Inc. | 3 | $74 |
| Agios Pharmaceuticals, Inc. | 3 | $73 |
| Exelixis Inc. | 3 | $67 |
| AbbVie | 4 | $64 |
| Mirati Therapeutics, Inc. | 2 | $51 |
| Boehringer Ingelheim | 2 | $49 |
| Geron Corporation | 2 | $43 |
| Bayer | 2 | $42 |
| Tactile Systems Technology Inc | 1 | $30 |
| Bard Peripheral Vascular, Inc. | 1 | $27 |
| Foundation Medicine, Inc. | 1 | $26 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Springworks Therapeutics, Inc. | 1 | $23 |
| Taiho Oncology, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,707 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 64 | $962,587 |
| RevlimidLenalidomide | 47 | $795,090 |
| PomalystPomalidomide | 27 | $694,219 |
| TagrissoOsimertinib Mesylate | 35 | $556,050 |
| ImbruvicaIbrutinib | 24 | $490,636 |
| IbrancePalbociclib | 31 | $468,517 |
| JakafiRuxolitinib Phosphate | 28 | $322,205 |
| Abiraterone Acetate | 36 | $291,808 |
| LumakrasSotorasib | 12 | $255,594 |
| ProcritEpoetin Alfa | 67 | $206,170 |
| CalquenceAcalabrutinib Maleate | 13 | $180,544 |
| ZytigaAbiraterone Acetate | 12 | $131,764 |
| VenclextaVenetoclax | 13 | $59,862 |
| AranespDarbepoetin Alfa In Polysorbat | 11 | $44,696 |
| ZenpepLipase/Protease/Amylase | 11 | $18,218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $222 | $795,09047 claims |
| AstraZenecaTagrisso, Calquence, Lokelma | $3,141 | $744,27959 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,178 | $694,21927 claims |
| PfizerIbrance, Eliquis | $82 | $478,62646 claims |
| Johnson & JohnsonProcrit, Zytiga | $1,044 | $337,93479 claims |
| Incyte CorporationJakafi | $134 | $322,20528 claims |
| AmgenLumakras, Aranesp | $370 | $300,29023 claims |
| AbbVieVenclexta, Creon | $64 | $76,45826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.
Other family in Brooklyn
- Seida VelijaBrooklyn$62K
- Ofiong OkonBrooklyn$44K
- Irina FainbergBrooklyn$23K
- Susan WeissBrooklyn$22K
- Razan AlawadhiBrooklyn$21K
- Christina LaoBrooklyn$20K
- Christina NalboneNew York$197K
- Casey GrilloNew York$191K
- Suzanne WilsonIthaca$179K
- Jonathan LesuerSyracuse$172K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.